Erste Group Bank Boosts Earnings Estimates for Astrazeneca

Astrazeneca Plc (NYSE:AZN) – Stock analysts at Erste Group Bank boosted their FY2027 earnings estimates for shares of Astrazeneca in a report issued on Friday, June 5th. Erste Group Bank analyst H. Engel now anticipates that the company will post earnings per share of $11.52 for the year, up from their prior forecast of $11.50. The consensus estimate for Astrazeneca’s current full-year earnings is $9.37 per share.

A number of other brokerages have also commented on AZN. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday. UBS Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Finally, Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Twelve investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Up 2.0%

Shares of NYSE:AZN opened at $182.48 on Friday. Astrazeneca has a 12 month low of $137.23 and a 12 month high of $212.71. The company’s 50-day moving average price is $189.75 and its two-hundred day moving average price is $185.85. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The firm has a market cap of $283.00 billion, a P/E ratio of 27.40, a P/E/G ratio of 1.56 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last announced its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. IHT Wealth Management LLC boosted its stake in shares of Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after purchasing an additional 54 shares during the last quarter. Visionary Wealth Advisors boosted its stake in shares of Astrazeneca by 1.5% in the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock valued at $737,000 after purchasing an additional 60 shares during the last quarter. Vista Investment Management boosted its stake in shares of Astrazeneca by 0.3% in the 4th quarter. Vista Investment Management now owns 21,215 shares of the company’s stock valued at $3,723,000 after purchasing an additional 60 shares during the last quarter. Kestra Investment Management LLC boosted its stake in shares of Astrazeneca by 1.9% in the 4th quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock valued at $595,000 after purchasing an additional 63 shares during the last quarter. Finally, Luken Investment Analytics LLC boosted its stake in shares of Astrazeneca by 4.3% in the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.